| [1] |
中华医学会核医学分会.
131I治疗分化型甲状腺癌指南(2014版)[J]. 中华核医学与分子影像杂志中华核医学与分子影像杂志, 2014, 34(4): 264-278.
doi: 10.3760/cma.j.issn.2095-2848.2014.04.002 Chinese Society of Nuclear Medicine. Guidelines for radioiodine therapy of differentiated thyroid cancer (2014 edition)[J]. Chin J Nucl Med Mol ImagingChin J Nucl Med Mol Imaging, 2014, 34(4): 264-278. doi: 10.3760/cma.j.issn.2095-2848.2014.04.002 |
| [2] |
中华医学会核医学分会.
131I治疗分化型甲状腺癌指南(2021版)[J]. 中华核医学与分子影像杂志中华核医学与分子影像杂志, 2021, 41(4): 218-241.
doi: 10.3760/cma.j.cn321828-20201113-00412 Chinese Society of Nuclear Medicine. Guidelines for radioiodine therapy of differentiated thyroid cancer (2021 edition)[J]. Chin J Nucl Med Mol ImagingChin J Nucl Med Mol Imaging, 2021, 41(4): 218-241. doi: 10.3760/cma.j.cn321828-20201113-00412 |
| [3] |
Cooper DS, Doherty GM, Haugen BR, et al.
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J]. ThyroidThyroid, 2009, 19(11): 1167-1214.
doi: 10.1089/thy.2009.0110 |
| [4] |
Haugen BR, Alexander EK, Bible KC, et al.
2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. ThyroidThyroid, 2016, 26(1): 1-133.
doi: 10.1089/thy.2015.0020 |
| [5] |
Greenhalgh T, Howick J, Maskrey N, et al.
Evidence based medicine: a movement in crisis?[J]. BMJBMJ, 2014, 348: g3725-.
doi: 10.1136/bmj.g3725 |
| [6] |
Tonelli MR.
The philosophical limits of evidence-based medicine[J]. Acad MedAcad Med, 1998, 73(12): 1234-1240.
doi: 10.1097/00001888-199812000-00011 |
| [7] |
姜礼红, 范鹰, 孟佳, 等.
如何正确处理循证医学与经验医学之间的关系[J]. 医学与哲学医学与哲学, 2010, 31(24): 1-2.
Jiang LH, Fan Y, Meng J, et al. How to deal with the relationship between evidence-based medicine and modern experimental medicine[J]. Med PhilosMed Philos, 2010, 31(24): 1-2. |
| [8] |
Rui ZY, Wu RX, Zheng W, et al.
Effect of 131I therapy on complete blood count in patients with differentiated thyroid cancer[J]. Med Sci MonitMed Sci Monit, 2021, 27: e929590-.
doi: 10.12659/MSM.929590 |
| [9] |
National Cancer Institute. Thyroid cancer—cancer stat facts[EB/OL]. [2023-07-27]. https://seer.cancer.gov/statfacts/html/thyro.html. |
| [10] |
Zeng HM, Chen WQ, Zheng RS, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries[J/OL]. Lancet Glob Health, 2018, 6(5): e555−e567[2023-07-27]. https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(18)30127-X/fulltext. DOI: 10.1016/S2214-109X(18)30127-X. |
| [11] |
黄乃思, 陈嘉莹, 嵇庆海, 等.
靶向药物时代局部晚期甲状腺癌的新辅助治疗[J]. 外科理论与实践外科理论与实践, 2021, 26(6): 493-496.
doi: 10.16139/j.1007-9610.2021.06.006 Huang NS, Chen JY, Ji QH, et al. New adjuvant treatment of locally advanced thyroid carcinoma in era of targeted therapy[J]. J Surg Cocepts PractJ Surg Cocepts Pract, 2021, 26(6): 493-496. doi: 10.16139/j.1007-9610.2021.06.006 |
| [12] |
季艳会, 王萱, 李雪, 等.
靶向药物治疗对碘难治性分化型甲状腺癌患者生命质量的短期影响[J]. 中华核医学与分子影像杂志中华核医学与分子影像杂志, 2022, 42(11): 656-660.
doi: 10.3760/cma.j.cn321828-20220729-00246 Ji YH, Wang X, Li X, et al. Short-term effect of targeted drugs on quality of life in patients with radioactive iodine-refractory differentiated thyroid cancer[J]. Chin J Nucl Med Mol ImagingChin J Nucl Med Mol Imaging, 2022, 42(11): 656-660. doi: 10.3760/cma.j.cn321828-20220729-00246 |